

IQVIA teams up with AstraZeneca to support COVID-19 vaccine development

16 July 2020 | News

This joint initiative is part of the U.S. government's recently announced Operation Warp Speed project



Leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry IQVIA has announced its collaboration with AstraZeneca to accelerate development of a potential new vaccine for COVID-19.

This joint initiative is part of the U.S. government's recently announced [Operation Warp Speed](#) project.

Operation Warp Speed is part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.

The specific IQVIA and AstraZeneca collaboration will drive faster delivery of clinical studies in the U.S. aimed at demonstrating efficacy of AstraZeneca's potential COVID-19 vaccine, AZD1222.

This initiative includes an expansive subject study, which is expected to begin enrolling participants this summer and will leverage IQVIA's [Virtual Trial solutions](#) including Study Hub.